CHU de Besançon
- Address
- 3 boulevard Jean Minjoz, 25030 Besançon, France
Oncology and Solid Tumor Research
At CHU de Besançon, clinical research in oncology focuses on improving care for people with advanced cancers, especially metastatic renal cell carcinoma and locally advanced cervical cancer. These studies are designed to assess whether newer treatment combinations can improve survival and disease control compared with current approaches.
- Testing combination immunotherapy strategies for metastatic renal cell carcinoma
- Evaluating new treatment options for cervical squamous and adenosquamous carcinoma
- Comparing approaches aimed at extending survival and delaying progression
This research reflects a strong interest in finding more effective therapies for difficult-to-treat cancers while supporting better long-term outcomes for patients.
Hematology and Transplantation Studies
The site also conducts research in hemic and lymphatic diseases, with a focus on patients undergoing haploidentical hematopoietic stem cell transplantation for hematological malignancies. The main goal is to improve transplant safety and effectiveness by refining supportive treatment strategies after transplantation.
- Studying ways to improve outcomes after haploidentical HSCT
- Assessing treatment strategies for hematological malignancies
- Seeking better balance between transplant recovery and complication prevention
These trials highlight an important area of blood cancer care, where researchers aim to make complex transplant procedures more successful and more manageable for patients.
Neurology and Regenerative Medicine
Research in nervous system diseases includes work on stroke, with attention to regenerative stem cell therapy as a possible way to support recovery. The studies are intended to explore whether innovative cell-based approaches can help improve outcomes after brain injury.
- Exploring new options for stroke recovery
- Investigating stem cell-based approaches in neurological care
- Aiming to support functional recovery after nervous system injury
This area shows the site’s broader interest in translating regenerative medicine into practical treatments for neurological disease.
Mixed Therapeutic Research
Some of the clinical activity at CHU de Besançon spans multiple therapeutic areas, combining neoplasms, hematologic disorders, and neurological conditions. Across these studies, the common purpose is to evaluate whether new treatment strategies can improve patient outcomes, refine care pathways, and expand options where current treatments remain limited.
- Broad clinical research across cancer, blood disease, and neurology
- Testing innovative therapies and treatment combinations
- Supporting better diagnosis, control, and recovery outcomes
With a small but focused portfolio, the site contributes to research aimed at advancing care in several important disease areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU de Besançon
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy Comparison of Nivolumab-Ipilimumab Versus Immune Checkpoint Inhibitor-VEGFR TKI Combinations in Untreated Metastatic Renal Cell Carcinoma | Institut Gustave Roussy | Phase III | Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Axitinib | 1 | Unknown | 2024-04-12 | 2024-04-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.